

Worldwide Healthcare Trust PLC



Investment Manager



Samuel D. Isaly

Information as at 31 January 2012

www.worldwidewh.com

Investment Objective and Benchmark Index


To invest worldwide in pharmaceutical, biotechnology and related companies in the healthcare sector with the aim of achieving a high level of capital growth. Performance is measured against the MSCI World Health Care Index with effect from 1 October 2010 (total return, sterling adjusted)*.

Cumulative Performance (%)

Trust: Worldwide Healthcare Trust PLC – NAV (total return; fully diluted)

Trust: Worldwide Healthcare Trust PLC – Share Price (total return)

Index: Blended DS/MSCI World Health Care Index (total return; £ adjusted)*



Discrete Performance – Calendar Years (%)

Percentage Growth	2007	2008	2009	2010	2011	YTD
NAV	4.0	16.9	6.8	17.7	7.3	2.4
Share Price	2.7	13.7	11.1	15.5	6.5	3.4
Index*	-0.3	19.4	4.2	8.7	10.0	0.7

Source: NAV (total return; fully diluted) & Share Price – Morningstar. Index - Thomson Reuters & Bloomberg. Past performance is not a guide to future performance.

*With effect from 1 October 2010, the performance of the Company is measured against the MSCI World Health Care Index on a total return, sterling adjusted basis. Prior to 1 October 2010, performance was measured against the Datastream World Pharmaceutical & Biotechnology Index (total return, sterling adjusted).

Commentary

In January the NAV (total return, sterling adjusted) was up 2.4%, the Share price total return was up 3.4% compared to the MSCI World Health Care Index (total return, sterling adjusted) which was up 0.7%.

Outperformance in January was clearly driven by relative fund positioning in both biotechnology and pharmaceuticals. First, our overweight in biotechnology stocks (both mid cap and large cap) was beneficial as the group ran on increased visibility on positive fundamentals. One key contributor included Gilead Sciences, Inc. as investors began to recognize the value of Gilead's acquisition of Pharmasset. The stock was up nearly 20% in the month. Additionally, Regeneron Pharmaceuticals announced better than expected sales of their newly launched drug treatment for blindness, Eylea (afibercept). The stock was up >50% in the month. Second, our underweight positioning in large cap pharmaceuticals was beneficial as the group severely underperformed and in fact traded down to start the year after outperforming in the previous month. Fourth-quarter reporting in January reminded investors that the challenges remain in this space – over half the companies guided to lower revenues and earnings for 2012. The key detractor in the month was Mitsubishi Tanabe Pharma. Gilenya (fingolimod) is the company's promising multiple sclerosis drug, licensed to and marketed globally by Novartis. Despite a solid first year of launch (global sales of \$500M reported in January), additional disclosures by Novartis over some patient deaths spooked investors and Mitsubishi Tanabe sold off >10%. We continue to believe in the positive risk/benefit profile afforded by Gilenya and thus we held the stock.

Biography

Samuel D. Isaly has been active in international and healthcare investment throughout his career, beginning at Chase Manhattan Bank. He studied international economics, mathematics and econometrics at Princeton and the London School of Economics. Mr Isaly joined SG Warburg and Company Inc in 1986 where he became a Senior Vice President. In March 1989, he became the initial founding partner of Mehta and Isaly. He became the initial founding partner of OrbiMed Capital LLC, created on January 1, 1998, upon the dissolution of Mehta and Isaly.

Investment Manager Profile

Investment management services are provided by OrbiMed Capital LLC (OrbiMed). OrbiMed is owned by seven principals, including Samuel D. Isaly, who have between them many years experience of valuing companies in the pharmaceutical, biotechnology and healthcare sectors. The US-based company employs over 40 experienced investment professionals who carry out extensive research, which involves company visits and developing an understanding of commercial prospects and development programmes for individual drugs. The company database covers some 600 international pharmaceutical and biotechnology companies, two thirds of which are actively researched. OrbiMed Capital LLC is registered as an investment adviser under the U.S. Securities and Exchange Commission.

Investment Policy

The Company offers a superior UK-listed opportunity for capital appreciation through a diversified portfolio of worldwide biotechnology, pharmaceutical, healthcare equipment, healthcare technology and healthcare services companies. The Investment Manager seeks to reduce risk through extensive fundamental research, worldwide exposure, position limits, and balanced market capitalisations. The Company's investment objectives also allow gearing of up to the lower of £90m or 20% of net assets and an exposure to derivative investments of up to 5% of the investment portfolio.

Discount Control Mechanism

The Directors have adopted an active discount management policy to establish and support an improved rating in the Company's shares through the use of share buybacks, with a view to limiting the discount to NAV per share at which the shares trade to no more than 6%. Shares bought back may be held in treasury for reissue at later dates at not more than the discount at which they were purchased, and in any event at a discount no greater than 5% to the prevailing net asset value per share. Any shares left in treasury are cancelled around the time of the AGM.

Worldwide Healthcare Trust PLC

10 Largest Holdings as at 31 January 2012 (% of total investments)

Name	Region	Total
Pfizer	North America	6.0
Roche	Europe	5.4
Novartis	Europe	5.0
Sanofi	Europe	4.3
Merck & Co	North America	3.9
Mitsubishi Tanabe Pharma	Japan	3.9
Gilead Sciences	North America	3.4
UnitedHealth	North America	2.9
Watson Pharmaceuticals	North America	2.8
Dendreon 2.875% 15/01/16	North America	2.7
Total		40.3

Sector, Geographical & Asset Class Breakdown as at 31 January 2012

Large Caps	67.1%	North America	65.5%	Equities	91.3%
Small Caps	32.9%	Europe	22.8%	Convertible Bonds	4.7%
Total	100.0%	Far East	11.1%	Fixed Interest Bonds	3.2%
		Israel	0.6%	Royalty Bonds	0.8%
		Total	100.0%	Total	100.0%

Source: All portfolio information sourced from Frostrow Capital LLP.

Share Price Total Return on £100 as at 31 January 2012 (£)

1 year	112.9
3 years	136.9
5 years	163.7

Source: Morningstar. Past performance is not a guide to future performance.

Standardised Discrete Performance (%)

Percentage Growth 12 Month Return	Jan 07- Jan 08	Jan 08- Jan 09	Jan 09- Jan 10	Jan 10- Jan 11	Jan 11- Jan 12
NAV	-2.7	24.0	7.9	12.0	12.1
Share Price	-2.5	22.6	9.6	10.6	12.9
Index*	-6.0	18.3	10.5	5.7	13.3

Source: NAV (total return; fully diluted) & Share Price – Morningstar. Index - Thomson Reuters and Bloomberg. Past performance is not a guide to future performance.

*With effect from 1 October 2010, the performance of the Company is measured against the MSCI World Health Care Index on a total return, sterling adjusted basis. Prior to 1 October 2010, performance was measured against the Datastream World Pharmaceutical & Biotechnology Index (total return, sterling adjusted).

Awards

Winner: Investment Week, Investment Trust Of The Year Awards 2010

Category: Specialist

Important Information

Worldwide Healthcare Trust PLC (the "Company") is a UK investment trust listed on the London Stock Exchange and is a member of the Association of Investment Companies. As this Company may implement a gearing policy investors should be aware that the share price movement may be more volatile than movements in the price of underlying investments. Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed. An investor may not get back the original amount invested. Changes in the rates of exchange between currencies may cause the value of investments to fluctuate. Fluctuation may be particularly marked in the case of a higher volatility fund and the value of an investment may fall suddenly and substantially. Shares in the biotechnology sector can prove volatile and above average price movements can be expected. There can be no assurance that the Company's investment objective will be achieved and investment results may vary substantially over time. This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Investment Trust share prices may not fully reflect underlying net asset values. There may be a difference between the prices at which you may purchase ("the offer price") or sell ("the bid price") a share on the stock market which is known as "bid-offer" or "dealing" spread. This is set by the market makers and varies from share to share. This spread typically averages 1-2% each way on the mid-market price (the price halfway between the bid and offer prices), and can fluctuate and at times be higher than average. Net Asset Value per share is calculated in accordance with the guidelines of the Association of Investment Companies in that income received by the Company in the period since the last annual accounts is excluded. Total net assets are stated inclusive of income received. Any opinions on individual stocks are those of the Company's Investment Manager and no reliance should be given on any such views. Any research in this document has been procured and may have been acted upon by OrbiMed Capital LLC for its own purposes. The results are being made available to you only incidentally. The views expressed herein do not constitute investment or any other advice and are subject to change. They do not necessarily reflect the views of Frostrow Capital LLP and no assurances are made as to their accuracy.

www.worldwidewh.com

Fast Facts as at 31 January 2012

Launch Date	April 1995
Annual Management Fee (payable by the Trust)	0.65% of net assets plus 0.30% of market cap. up to £150m and 0.20% > £150m and 0.125% > £500m plus £57,500
Performance Fee	See Annual Report for details
Continuation Vote	At AGM in 2014; every 5 years
Year / interim end	31 March / 30 September
Capital Structure	43,213,962 Ordinary Shares 7,754,310 Subscription Shares 308,301 Treasury Shares

Trust Characteristics

Number of Holdings	59
Net Assets (£m)	365.6
Dividend Policy	Provisional Date: June
Yield	2.0%
Gearing (AIC basis)	106
Share Price (p)	758.00
Subs. Share Price (p)	116.00
NAV (p) undiluted *	845.98
NAV (p) diluted: subscription shares *	814.34
NAV (p) diluted: subscription shares & treasury shares *	814.00
(Discount) / Premium	Undiluted (10.4%)
(Discount) / Premium	Diluted Sub Shares (6.9%)
(Discount) / Premium	Fully Diluted (6.9%)

*capital only

Codes

Sedol – Shares	0338530
ISIN – Shares	GB0003385308
Bloomberg – Shares	WWH LN
Epic – Shares	WWH
Sedol – Sub Shares	B3VMCB0
ISIN – Sub Shares	GB00B3VMCB07
Bloomberg – Sub Shares	WWHS LN

How to Contact Us

Frostrow Capital LLP
25 Southampton Buildings, London, WC2A 1AL
Tel.: 0203 0084910
Fax: 0203 0438889
Website: www.frostrow.com

Grant Challis
Tel.: 0203 0084912
grant.challis@frostrow.com

Authorised and regulated by the Financial Services Authority.

